Back to Research Home
REGNRegeneron Pharmaceuticals Inc
Health Care · Biotechnology · Large
$805.02−1.72%
As of 23 Oct 2026Mkt cap $87.7B
Stage 13
WAIT
Fundamentals
49.5/75
Technical
8.2/15
Independent
57.7/90
GCAE viewelevated earnings event risk blocks an independent BUY decision
Price
- 1M
- +1.1%
- 3M
- +20.7%
- 6M
- +7.1%
- 1Y
- +37.7%
Financials & valuation
Cached filing evidence · as of 2026-10-02
Valuation
- P/E
- 19.9xHist median 17.7x
- Forward P/E
- —No validated forward-estimate source
- Price / FCF
- 23.2x
- FCF yield
- 4.3%
Quality
- ROIC
- 10.4%
- Operating margin
- 28.1%
- FCF margin
- 28.4%
- Current ratio
- 4.1x
Growth
- Revenue growth
- +1.0%Latest FY YoY
- Revenue CAGR
- −2.8%
- EPS CAGR
- −12.9%
- FCF CAGR
- −11.1%
Capital
- Share-count trend
- −2.3%3Y annualised
- Net cash
- $865M-0.2x OCF
Annual trend
- CAGR 2021–2025
- −2.8%
- Latest · 2025
- $14B
- YoY
- +1.0%
GCAE Research
- Quality Research
- NOT FLAGGED
- Acceleration Radar
- NOT FLAGGED
- THE ONE
- NOT FLAGGED
- Final / Opportunity
- NOT FLAGGED
Key takeaway
elevated earnings event risk blocks an independent BUY decision
Unresolved question
No reliable unresolved question is available from the current committed evidence.
Watch next
- Next earnings · 2026-10-30
More details & evidence
Production decision
- Stage 13
- WAIT
- Technical state
- approaching-support
- Rotation
- tailwind
- Evidence
- fresh
Presentation freshness
- Stage 11 market
- 2026-10-23 · Massive
- Financial cache
- 2026-10-02
- Quality Research
- NOT FLAGGED
- THE ONE
- NOT FLAGGED
Authority
- Company page
- Presentation only
- Scores
- Frozen GCAE production outputs
- Research
- Research-only lanes; no score override
- Private portfolio
- Not loaded